This study found that immunotherapies such as cytokine-based therapies, ICIs such as mAbs, anti-KIT antibodies, and cellular therapies with mAbs are currently being used to treat GIST, adenocarcinoma subtype, and lymphoma. This evidence concerns the gene KIT and gastrointestinal stromal tumor.